Zhong-Hua Wang

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Yi-Zhou Jiang, Yin Liu, Yi Xiao et al. · Cell Research · 2020 · 314 citations · Full text

Medicine, Oncology, Pharmacology +16

Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial

Xi-Chun Hu, Jian Zhang, Bing-He Xu et al. · The Lancet Oncology · 2015 · 285 citations

Medicine, Oncology, Pharmacology +15

Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer

Bi-Yun Wang, Jian Zhang, Jia-Lei Wang et al. · Journal of Experimental & Clinical Cancer Research · 2015 · 179 citations · Full text

Medicine, Oncology, Pharmacology +15

The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancer

Jian Zhang, Joseph Ragaz, Ying-Jian Zhang et al. · BMC Cancer · 2013 · 33 citations · Full text

Medicine, Oncology, Breast Oncology +14

The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells

Lei-Ping Wang, Jun Cao, Jian Zhang et al. · Medical Oncology · 2015 · 22 citations

Life Sciences, Cancer Biology, Cell Biology +16